Total Payments
$234,542
2022 Payments
$91.87
Companies
7
Transactions
25
Payment Breakdown by Category
Research$233,794 (99.7%)
Food & Beverage$748.79 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $233,794 | 17 | 99.7% |
| Food and Beverage | $748.79 | 8 | 0.3% |
Payments by Type
Research
$233,794
17 transactions
General
$748.79
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Glenmark Pharmaceuticals Inc. | $233,794 | 17 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $264.94 | 3 | $0 (2022) |
| Circassia Pharmaceuticals Inc | $125.00 | 1 | $0 (2017) |
| Genentech USA, Inc. | $125.00 | 1 | $0 (2017) |
| Teva Pharmaceuticals USA, Inc. | $101.43 | 1 | $0 (2017) |
| Phadia US Inc. | $84.38 | 1 | $0 (2018) |
| Shire North American Group Inc | $48.04 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $91.87 | 1 | AstraZeneca Pharmaceuticals LP ($91.87) |
| 2019 | $221.11 | 3 | AstraZeneca Pharmaceuticals LP ($173.07) |
| 2018 | $84.38 | 1 | Phadia US Inc. ($84.38) |
| 2017 | $234,145 | 20 | Glenmark Pharmaceuticals Inc. ($233,794) |
All Payment Transactions
25 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/08/2022 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $91.87 | General |
| Category: Respiratory | ||||||
| 04/06/2019 | Shire North American Group Inc | CINRYZE (Drug) | Food and Beverage | In-kind items and services | $48.04 | General |
| Category: IMMUNOLOGY | ||||||
| 04/05/2019 | AstraZeneca Pharmaceuticals LP | FASENRA (Drug) | Food and Beverage | In-kind items and services | $63.06 | General |
| Category: Respiratory | ||||||
| 01/24/2019 | AstraZeneca Pharmaceuticals LP | FASENRA (Drug) | Food and Beverage | In-kind items and services | $110.01 | General |
| Category: Respiratory | ||||||
| 07/19/2018 | Phadia US Inc. | ImmunoCAP (Device) | Food and Beverage | Cash or cash equivalent | $84.38 | General |
| Category: Allergy/Immunology | ||||||
| 12/20/2017 | Glenmark Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $74.00 | Research |
| Study: GSP301-304 | ||||||
| 10/12/2017 | Glenmark Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $15,670.00 | Research |
| Study: GSP 301-303 | ||||||
| 10/10/2017 | Genentech USA, Inc. | Xolair (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Immunology | ||||||
| 08/29/2017 | Circassia Pharmaceuticals Inc | NIOX VERO DEVICE (Device) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ALLERGY AND ASTHMA | ||||||
| 06/22/2017 | Glenmark Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $9,540.00 | Research |
| Study: GSP 301-303 | ||||||
| 05/12/2017 | Glenmark Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $27,611.28 | Research |
| Study: GSP301-304 | ||||||
| 05/10/2017 | Glenmark Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $1,000.00 | Research |
| Study: GSP301-304 | ||||||
| 05/10/2017 | Glenmark Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $169.20 | Research |
| Study: GSP301-304 | ||||||
| 05/04/2017 | Glenmark Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $13,500.00 | Research |
| Study: GSP 301-303 | ||||||
| 04/10/2017 | Teva Pharmaceuticals USA, Inc. | CINQAIR (Drug) | Food and Beverage | In-kind items and services | $101.43 | General |
| Category: Respiratory | ||||||
| 04/05/2017 | Glenmark Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $27,630.00 | Research |
| Study: GSP 301-303 | ||||||
| 04/05/2017 | Glenmark Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $500.00 | Research |
| Study: GSP301-304 | ||||||
| 03/29/2017 | Glenmark Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $600.00 | Research |
| Study: GSP301-304 | ||||||
| 03/09/2017 | Glenmark Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $11,010.00 | Research |
| Study: GSP 301-303 | ||||||
| 03/08/2017 | Glenmark Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $1,650.00 | Research |
| Study: GSP301-304 | ||||||
| 03/03/2017 | Glenmark Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $744.00 | Research |
| Study: GSP301-304 | ||||||
| 03/01/2017 | Glenmark Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $9,900.00 | Research |
| Study: GSP301-304 | ||||||
| 02/17/2017 | Glenmark Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $109,122.12 | Research |
| Study: GSP301-304 | ||||||
| 02/17/2017 | Glenmark Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $1,323.00 | Research |
| Study: GSP301-304 | ||||||
| 01/18/2017 | Glenmark Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $3,750.00 | Research |
| Study: GSP301-304 | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| GSP301-304 | Glenmark Pharmaceuticals Inc. | $156,444 | 12 |
| GSP 301-303 | Glenmark Pharmaceuticals Inc. | $77,350 | 5 |
About Dr. Julius Van Bavel, M.D
Dr. Julius Van Bavel, M.D is a Allergy healthcare provider based in Austin, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1396718516.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Julius Van Bavel, M.D has received a total of $234,542 in payments from pharmaceutical and medical device companies, with $91.87 received in 2022. These payments were reported across 25 transactions from 7 companies. The most common payment nature is "" ($233,794).
Ad
Practice Information
- Specialty Allergy
- Location Austin, TX
- Active Since 02/08/2006
- Last Updated 07/25/2007
- Taxonomy Code 207KA0200X
- Entity Type Individual
- NPI Number 1396718516
Products in Payments
- FASENRA (Drug) $173.07
- NIOX VERO DEVICE (Device) $125.00
- Xolair (Biological) $125.00
- CINQAIR (Drug) $101.43
- TEZSPIRE (Biological) $91.87
- ImmunoCAP (Device) $84.38
- CINRYZE (Drug) $48.04
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.